TRIALS UPDATE: The Latest Alzheimer’s Drug Development News (Q1 2025)
This installment of our quarterly Trials Update captures the latest developments in Alzheimer’s and other dementia clinical trials, from January 2025 to present. We’ve…
This installment of our quarterly Trials Update captures the latest developments in Alzheimer’s and other dementia clinical trials, from January 2025 to present. We’ve…
Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are changeable — they…
What happens when Alzheimer’s — a disease that strikes minority communities the hardest — is largely studied in well-educated whites? Is Alzheimer’s research one-size-fits…
Eleven years after Dr. Miia Kivipelto’s landmark FINGER trial demonstrated that lifestyle changes can help protect the brain, researchers continue to discover how the…
More than a decade ago, Alzheimer’s vaccines appeared in clinical trials — but failed. Now several companies are gearing up to test the next…
A person who struggles with tasks they’ve been doing for years or asks the same question over and over again may be showing the…
Scientists developed new brain cells to replace those lost in Parkinson’s. Early trials showed they’re safe — now, larger human trials are on the…
Your genetics could make you more vulnerable to the side effects of the new class of Alzheimer’s drugs. Carrying two copies of the ApoE4…
Treatment with a powerful magnet is one of the newest experimental therapies being used to try to turn back the clock on Alzheimer’s disease….
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
Could a headset with flashing lights and sounds stimulate brain waves and treat Alzheimer’s? Cognito’s Phase 3 trial on such a device is trying…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
ApoE4, a genetic variation sometimes referred to as the “Alzheimer’s gene,” is one of the most influential genetic risk factors for developing Alzheimer’s disease….
A Trump executive order has banned DEI initiatives across the federal government. Scientists say the move could undermine trial diversity and derail the quest…